Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis.
Defatting
Human hepatocytes
Human precision-cut liver slices
Liver transplantation
Steatosis
Triglycerides
Journal
Disease models & mechanisms
ISSN: 1754-8411
Titre abrégé: Dis Model Mech
Pays: England
ID NLM: 101483332
Informations de publication
Date de publication:
29 04 2020
29 04 2020
Historique:
received:
04
10
2019
accepted:
13
02
2020
pubmed:
26
2
2020
medline:
11
6
2021
entrez:
26
2
2020
Statut:
epublish
Résumé
Normothermic perfusion provides a means to rescue steatotic liver grafts, including by pharmacological defatting. In this study, we tested the potential of new drug combinations to trigger defatting in three human culture models, primary hepatocytes with induced steatosis, primary hepatocytes isolated from steatotic liver, and precision-cut liver slices (PCLS) of steatotic liver. Forskolin, L-carnitine and a PPARα agonist were all combined with rapamycin, an immunosuppressant that induces autophagy, in a D-FAT cocktail. D-FAT was tested alone or in combination with necrosulfonamide, an inhibitor of mixed lineage kinase domain like pseudokinase involved in necroptosis. Within 24 h, in all three models, D-FAT induced a decrease in triglyceride content by 30%, attributable to an upregulation of genes involved in free fatty acid β-oxidation and autophagy, and a downregulation of those involved in lipogenesis. Defatting was accompanied by a decrease in endoplasmic reticulum stress and in the production of reactive oxygen species. The addition of necrosulfonamide increased the efficacy of defatting by 8%-12% in PCLS, with a trend towards increased autophagy. In conclusion, culture models, notably PCLS, are insightful to design strategies for liver graft rescue. Defatting can be rapidly achieved by combinations of drugs targeting mitochondrial oxidative metabolism, macro-autophagy and lipogenesis.
Identifiants
pubmed: 32094147
pii: dmm.042663
doi: 10.1242/dmm.042663
pmc: PMC7197711
pii:
doi:
Substances chimiques
Acrylamides
0
Fatty Acids
0
N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide
0
Sulfonamides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing or financial interests.
Références
Hepatol Int. 2019 Jan;13(1):51-57
pubmed: 30515676
Lab Invest. 2016 Jun;96(6):672-9
pubmed: 26950484
PLoS One. 2018 Jul 25;13(7):e0201419
pubmed: 30044872
J Biol Chem. 1957 May;226(1):497-509
pubmed: 13428781
J Hepatol. 2013 May;58(5):993-9
pubmed: 23339953
World J Gastroenterol. 2014 Sep 28;20(36):12956-80
pubmed: 25278691
FASEB J. 2007 May;21(7):1433-44
pubmed: 17283223
Hepatol Res. 2016 Aug;46(9):933-43
pubmed: 26666995
Curr Opin Organ Transplant. 2017 Dec;22(6):555-562
pubmed: 28922300
Biochim Biophys Acta. 2013 Feb;1831(2):387-97
pubmed: 22951416
Transplantation. 1992 Jul;54(1):167-70
pubmed: 1631928
Liver Transpl. 2019 Jul;25(7):1007-1022
pubmed: 30821045
Chem Biol Interact. 2007 Jan 30;165(2):106-16
pubmed: 17188672
Mol Metab. 2019 May;23:14-23
pubmed: 30837196
Nat Commun. 2016 Jun 21;7:11869
pubmed: 27323669
Am J Clin Nutr. 2002 Oct;76(4):750-7
pubmed: 12324287
Biochem Biophys Res Commun. 2016 Jan 22;469(4):1104-10
pubmed: 26687947
J Biol Chem. 1993 Jun 15;268(17):12713-8
pubmed: 8509406
Diabetes. 2010 Apr;59(4):775-81
pubmed: 20068142
Nat Protoc. 2010 Sep;5(9):1540-51
pubmed: 20725069
J Hepatol. 2013 Dec;59(6):1307-14
pubmed: 23872604
Metabolism. 2007 Nov;56(11):1500-7
pubmed: 17950100
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Am J Transplant. 2012 Sep;12(9):2477-86
pubmed: 22594953
Metab Eng. 2009 Jul-Sep;11(4-5):274-83
pubmed: 19508897
Hepatology. 2018 Aug;68(2):496-514
pubmed: 29457836
Cell Biol Int. 2018 Sep;42(10):1282-1291
pubmed: 29908010
PLoS One. 2016 Jul 20;11(7):e0159729
pubmed: 27438262
J Hepatol. 2017 Sep 21;:
pubmed: 28870676
Curr Opin Lipidol. 2012 Jun;23(3):226-34
pubmed: 22449814
Exp Gerontol. 2016 Oct;83:130-8
pubmed: 27498120
Hum Mol Genet. 2019 Jan 1;28(1):143-154
pubmed: 30256948